Chemotherapy Treatment Modifications During the COVID-19 Outbreak at a Community Cancer Center in New York City
| Autor: | Trishala Meghal, Yiqing Xu, Lan Mo, Dong D. Lin, Pooja Murthy, Ashley D'Silva, Yiwu Huang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Coronavirus disease 2019 (COVID-19) medicine.medical_treatment Pneumonia Viral Antineoplastic Agents Disease Medical Oncology Betacoronavirus Neoplasms Pandemic Original Reports medicine Humans Pandemics Neoadjuvant therapy Aged Aged 80 and over Chemotherapy business.industry SARS-CoV-2 Palliative Care Outbreak Cancer COVID-19 Community Health Centers Middle Aged Patient Acceptance of Health Care medicine.disease Neoadjuvant Therapy Pneumonia Oncology Emergency medicine Female New York City business Coronavirus Infections |
| Zdroj: | JCO Global Oncology |
| ISSN: | 2687-8941 |
| Popis: | PURPOSE As a result of their immunocompromised status associated with disease and treatment, patients with cancer face a profound threat for higher rates of complications and mortality if they contract the coronavirus disease 2019 infection. Medical oncology communities have developed treatment modifications to balance the risk of contracting the virus with the benefit of improving cancer-related outcomes. METHODS We systemically examined our community cancer center database to display patterns of change and to unveil factors that have been considered with each decision. We studied a cohort of 282 patients receiving treatment and found that 159 patients (56.4%) had treatment modifications. RESULTS The incidence of treatment modification was observed in patients undergoing adjuvant and neoadjuvant (41.4%), palliative (62.9%), or injectable endocrine or bone-modulating only (76.0%) treatments. Modifications were applied to regimens with myelosuppressive (56.5%), immunosuppressive (69.2%), and immunomodulating (61.5%) potentials. These modifications also affected intravenous (54.9%) and subcutaneous injectable treatments (62.5%) more than oral treatments (15.8%). Treatment modifications in 112 patients (70.4%) were recommended by providers, and 47 (29.6%) were initiated by patients. The most common strategy of modification was to skip or postpone a scheduled treatment (49%). Among treatment with no modifications, treatment regimens were maintained in patients who tolerated treatment well (37.0%), in treatments with curative intent (22%), and in symptomatic patients who required treatment (14%). CONCLUSION Our observation and analysis suggested that the primary goal of treatment modification was to decrease potential exposure. The pattern also reflected the negative impact of the pandemic on health care providers who initiated these changes. Providers have to consider individualized recommendations incorporating multiple factors, such as tolerance, potential toxicity, treatment nature and route, and disease severity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|